Trinity Biotech Announces Collaboration with University at Buffalo to Commercialise Novel Biomarkers for Sjögren’s Syndrome

Trinity Biotech plc, a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has entered into a collaboration agreement with the University at Buffalo, New York (UB). The partnership focuses on advancing and commercialising a suite of proprietary biomarkers for the earlier and more accurate detection of Sjögren’s Syndrome, one of the most common but underdiagnosed autoimmune diseases.

This collaboration is a key strategic milestone in the continued expansion of Trinity Biotech’s New York State Department of Health – approved reference laboratory (NYSDOH), underpinning its strategy to commercialise high-value speciality diagnostic tests in the U.S. market.

Sjögren’s Syndrome is a chronic, systemic autoimmune disease that primarily affects moisture-producing glands in the eyes and mouth, with potential progressive involvement of multiple organ systems. The disease may affect the nervous system, lungs, and kidneys as well as the function of most other exocrine glands in the human body. Chronic fatigue, joint pain, and neuropathic pain are significant sources of disability.

It is widely underdiagnosed and often mistaken for other autoimmune or inflammatory conditions. As many as 4 million people in the United States may be living with Sjögren’s, three times more common than better-known related diseases such as lupus and multiple sclerosis. Women account for approximately 90% of cases, and diagnosis is often delayed for years due to heterogeneous clinical presentation1.

The unmet clinical need remains substantial, with traditional diagnostic pathways heavily reliant on subjective symptom reporting and invasive testing. Trinity Biotech’s collaboration with UB aims to unlock a new generation of objective, biomarker-based tests to enhance diagnostic speed, accuracy, and clinical confidence.